The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

A Multi-center, Randomized, Double-blinded, Phase III Trial of SHR-1316 or Placebo in Combination With Chemo-radiotherapy in Patients With Limited-stage Small-cell Lung Cancer.

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04691063

Enrollment

486

Registered

2020-12-31

Start date

2021-01-22

Completion date

2025-05-15

Last updated

2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-cell Lung Cancer

Brief summary

The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.

Interventions

DRUGSHR-1316; Carboplatin; Etoposide；Radiotherapy

SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）

DRUGPalcebo; Carboplatin; Etoposide；Radiotherapy

Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

SHR-1316 in combination with chemo-radiotherapy.

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Male or female, 18-75 years of age. 2. Subjects with histologically confirmed Limited-Stage SCLC without previous systematic treatment. 3. ECOG PS 0\ 1. 4. At least 1 measurable lesion as defined by RECIST v1.1. 5. Adequate organ function. 6. Female subjects of childbearing potential or male subjects must be willing to use a recognized effective contraceptive measure during the study and within 3 months after the last dose of the study drug. And female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose. 7. Signed the informed consent form.

Exclusion criteria

1. Mixed SCLC or NSCLC. 2. Subjects who previously received systemic antitumor or Immune checkpoint inhibitor therapy. 3. Extensive-stage SCLC. 4. Subjects who is surgically resectable. 5. Subjects with malignant pleural effusion. 6. Subjects highly suspected of interstitial lung disease, or with conditions that may interfere with the testing or management of suspected treatment-related pulmonary toxicities, or other moderate to severe diseases that seriously affect pulmonary function. 7. Active, known, or suspected autoimmune diseases. 8. History of malignant tumors. 9. Subjects with severe cardiovascular disease. 10. Events of arterial/venous thrombosis within 6 months prior to the first dose. 11. Subjects with serious infection. 12. Subjects with active pulmonary tuberculosis (TB). 13. Subjects with immunodeficiency diseases. 14. Subjects with active hepatitis B virus or hepatitis C virus infection. 15. Systemic immunosuppressants administation within 14 days prior to the first dose. 16. Subjects who received major surgery within 28 days prior to the first dose. 17. Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose. 18. Subjects who have previously received tissue/organ transplants. 19. Subjects with history of severe allergic reactions to monoclonal antibodies/fusion protein drugs. 20. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or substance abuse.

Design outcomes

Primary

Measure	Time frame	Description
OS	up to 36 months	Overall Survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026